Aquapharm appoints new Chief Scientific Officer
Aquapharm Biodiscovery announced the appointment of Dr Tim Morley as Chief Scientific Officer (CSO). Dr Morley’s appointment follows an investment of £4.2 million from existing investors and the appointments of biotech entrepreneur Simon Best as CEO and Aquapharm’s founder Dr Andrew Mearns-Spragg as CTO in March 2010.
In his new role at Aquapharm, Dr Morley will be responsible for leading Aquapharm’s in-house R&D programmes which address both pharmaceutical and non-pharma functional ingredient opportunities for the personal care and nutrition industries. Dr Morley has over 20 years experience in the pharmaceutical industry, which will prove invaluable as the company develops novel marine derived drug candidates. Dr Morley gained his PhD in Mechanistic Toxicology at Aberdeen University and holds an MSc in Biopharmacy, BSc in Pharmacology and BSc in Biochemistry.
Dr Morley’s previous positions include Research and Strategic Project Director at Quotient Biodiagnostics, Vice President Preclinical Sciences at Ardana Bioscience and Senior Director Molecular & Cellular Pharmacology at Vernalis R&D Ltd. Dr Morley has directed the development of compounds for the treatment of prostate cancer, growth hormone deficiency, obesity, and Parkinsons disease from discovery to clinical trials. Vernalis’ Parkinsons product V2006 is currently in Phase II clinical trials and was successfully partnered with Biogen-Idec in 2004.
Other news from the department people
